

**Kallikrein 9 Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP6328b****Specification**

---

**Kallikrein 9 Antibody (Center) Blocking peptide - Product Information**Primary Accession [Q9UKQ9](#)**Kallikrein 9 Antibody (Center) Blocking peptide - Additional Information****Gene ID** 284366**Other Names**

Kallikrein-9, 3421-, Kallikrein-like protein 3, KLK-L3, KLK9

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6328b](/product/products/AP6328b) was selected from the Center region of human KLK9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**Kallikrein 9 Antibody (Center) Blocking peptide - Protein Information****Name** KLK9**Cellular Location**

Secreted.

**Tissue Location**

Skin, thymus, trachea, cerebellum and spinal cord.

**Kallikrein 9 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**Kallikrein 9 Antibody (Center) Blocking peptide - Images****Kallikrein 9 Antibody (Center) Blocking peptide - Background**

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK9 is a novel kallikrein with potential application for diagnosis, monitoring and therapeutics of various cancers including those of the breast, prostate and testis.

**Kallikrein 9 Antibody (Center) Blocking peptide - References**

Yousef, G.M., et al., Cancer Res. 61(21):7811-7818 (2001).Yousef, G.M., et al., Genomics 65(2):184-194 (2000).Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).Yousef, G.M., et al., Anticancer Res. 19 (4B), 2843-2852 (1999).